Schroder Investment Management Boosts Stake in Exact Sciences

Investment firm increases holdings in medical research company by nearly 50%

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Schroder Investment Management Group grew its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 49.3% during the 3rd quarter, according to the company's recent SEC filing. The fund now owns approximately 1.2 million shares of the medical research company's stock, valued at $64.6 million.

Why it matters

Exact Sciences is a leading molecular diagnostics company focused on early cancer detection and prevention. Schroder's increased investment signals confidence in the company's growth potential and the continued demand for its flagship product, the Cologuard colorectal cancer screening test.

The details

Schroder Investment Management Group purchased an additional 399,665 shares of Exact Sciences during the third quarter, bringing its total holdings to 1,210,865 shares. This represents approximately 0.64% of Exact Sciences' outstanding shares. The investment firm cited the company's strong performance and future growth prospects as reasons for increasing its stake.

  • Schroder Investment Management Group grew its holdings in Exact Sciences during the 3rd quarter of 2026.

The players

Schroder Investment Management Group

A global asset management firm that provides investment products and services to institutional and retail clients worldwide.

Exact Sciences Corporation

A molecular diagnostics company headquartered in Madison, Wisconsin, focused on early cancer detection and prevention. The company's flagship product is the Cologuard colorectal cancer screening test.

Got photos? Submit your photos here. ›

The takeaway

Schroder's increased investment in Exact Sciences reflects the growing demand and potential for the company's cancer screening technologies, particularly its Cologuard test. This signals continued confidence in Exact Sciences' ability to drive innovation and growth in the molecular diagnostics market.